Genotype 1a

TABLE 108: SVR GENOTYPE 1A TREATMENT-EXPERIENCED WITH PRIOR RELAPSE: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

| TREATMENT | REFERENCE | RR (95% CRI) | RD % (95% CRL) |
|--------------------------------------|-------------------------------|-------------------------|------------------------|
| SIM12 PR24-48 RGT | PR48 | 2.62 (1.85 to 3.60) | 45.63 (26.75 to 60.65) |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | | 3.30 (2.51 to 4.36) | 64.94 (48.52 to 73.97) |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | SIM12 PR24-48 RGT | 1.26 (0.98 to 1.66) | 19.08 (–2.04 to 37.74) |
| | | | |
| Random effect model | Residual deviance | 5.624 vs. 6 data points | |
| | Deviance information criteria | 33.823 | |
| Fixed effect model | Residual deviance | 5.68 vs. 6 data points | |
| | Deviance information criteria | 33.668 | |

CrI = credible interval; DAS = dasabuvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.